Blinatumomab, a bispecific monoclonal Ab that directs CD3 + T cells to lyse CD19 + leukemic blasts, has been shown to achieve minimal residual disease (MRD)-negative remissions in adult and pediatric patients with relapsed or refractory pre-B ALL, even after hematopoietic cell transplant (HCT). [1] [2] [3] [4] [5] [6] [7] [8] However, reports of blinatumomab as a bridge therapy for HCT in pediatric patients with relapsed/refractory ALL remain limited. 1, 5, 8 Our experience in treating relapsed or refractory pediatric ALL is that blinatumomab is an efficacious and well-tolerated therapy that induces molecular MRD in heavily pre-treated patients, allowing them to proceed to allogeneic HCT with good organ function, excellent performance status and free of opportunistic infections.
From April 2015 through November 2016, five patients aged between 2 and 20 years with relapsed or refractory ALL were treated with blinatumomab as a continuous infusion at 15 μg/m 2 / day for 28 days per cycle. All patients achieved MRD-negative CR following blinatumomab and proceeded to myeloablative HCT. They all remain disease-free 9-19 months post HCT (Table 1) . Local IRB approval was obtained to review and report these findings. We concentrate our discussion on three of the patients (patients nos. 3, 4 and 5, Table 1 ) that illustrate clear advantages of blinatumomab over other available therapeutic options for relapsed/refractory ALL.
Patient no. 5 was diagnosed with central nervous system 2a, pre-B ALL at 18 months of age. His day 29 post-induction MRD by flow cytometry was 0.025%. He achieved negative MRD following consolidation. He developed isolated central nervous system 3 relapse at 15 months from diagnosis and proceeded to a 4/6 unrelated cord blood transplant at another center. Post-transplant day +18 bone marrow (BM) biopsy showed 100% donor chimerism with no evidence of leukemia, however, he developed a BM and central nervous system relapse on day +74. He was started on chemotherapy and was enrolled in an anti-CD19 chimeric Ag receptor T-cell (CAR-T) therapy trial at a different center. He achieved CR after CAR-T infusion no. 1, but lost the CAR-T cells at day +63 post infusion. He then received CAR-T no. 2, which were not detectable by day +21 post infusion. He was found to have a third isolated BM relapse 3 months post CAR-T no. 2 and was started on re-induction chemotherapy, resulting in a partial response with 2.3% CD19 + BM blasts. He subsequently received CAR-T no. 3, which were also short-lived. The family decided to proceed with another anti-CD19 CAR-T cell trial at a different institution. As bridge therapy, the patient received 4 weeks of chemotherapy. His pre-CAR-T cell infusion BM blasts were 4.8% increasing to 77% 23-day post CAR-T no. 4 while remaining CD19
+ . He returned to our center where he received 2 weeks of three-drug re-induction followed by 4 weeks of blinatumomab that led to a MRD-negative remission. He then underwent a second HCT, which was haploidentical. He is now 9 months post BMT with negative MRD and 100% donor chimerism. This patient's disease course highlights the efficacy of blinatumomab in treating relapsed refractory ALL that failed anti-CD19 CAR-T cell therapy. T-cell-engaging immunotherapy including blinatumomab and anti-CD19 CAR-T cell therapy has revolutionized treatment of patients with high-risk relapsed/ refractory ALL. CAR-T cell therapy has shown promising efficacy in clinical trials. [9] [10] [11] Various mechanisms may contribute to CAR-T cell therapy failure including: lack of durable persistence of infused CAR-T cells, intrinsic resistance to CAR-T cells and evolution of CD19 escape variants. The patient achieved CR with blinatumomab immediately following CAR-T cell therapy failure when durable CAR-T cell persistence was not achieved, suggesting effective endogenous T-cell function and absence of leukemic cell intrinsic resistance mechanisms.
Despite 67-90% remission rate in adult and pediatric patients with relapsed/refractory ALL treated with anti-CD19 CAR-T cell therapy, 9-11 a number of drawbacks exist with current CAR-T cell therapy, such as: (1) limited availability through clinical trials; (2) severe cytokine release syndrome in 27-43% of the patients; [9] [10] [11] (3) requirement of adequate absolute lymphocyte counts for CAR-T cell production; and (4) need for apheresis catheter for peripheral blood T-cell collection. Overall, the amount of time and resources involved in CAR-T cell therapy far exceeds what is required for blinatumomab treatment. Comparison between anti-CD19 CAR-T cell therapy and blinatumomab warrants further study. Patient no. 3 was diagnosed with Philadelphia-positive (Ph+) (BCR-ABLp190) ALL at 12 years of age. He achieved MRD of 0.19% after induction chemotherapy and dasatinib. He achieved CR with negative BM MRD and BCR-ABL quantitative PCR after consolidation chemotherapy. He was noted to have leukemic infiltrates in his left eye with M3 BM and a V299L mutation at 16 months from diagnosis. He was re-induced with chemotherapy and nilotinib. He developed invasive left maxillary zygomycetes infection with erosion into the orbital wall and palate, which progressed despite extensive surgical debridement. He did not tolerate amphotericin B treatment and remained pancytopenic. Nilotinib was discontinued due to grade IV hepatic toxicity. The patient was discharged to palliative care per family's request. While home for 6 weeks, he clinically improved and returned for treatment. His WBC count had recovered and his zygomycetes infection surprisingly remained contained. Repeat BM biopsy demonstrated CR with negative BCR-ABL qPCR. He was treated with liposomal amphotericin B followed by aggressive surgical debridement, left orbital enucleation, left maxillectomy and reconstruction. Blinatumomab was started in combination with ponatinib, which he tolerated well. He developed fever, headache, pain and cytokine release syndrome during the first 2 days of blinatumomab infusion but otherwise tolerated treatment well. He received five cycles of blinatumomab without neutropenia (Figure 1 ) allowing adequate anti-fungal treatment in preparation for BMT. His BM biopsy confirmed MRD negativity and continued molecular remission. He underwent haploidentical bone marrow transplantation and is currently in remission with complete donor engraftment 415 months post transplant.
Blinatumomab is currently FDA-approved for patients with Philadelphia-negative (Ph − ) ALL. A recent phase II clinical trial demonstrated that blinatumomab, as a single agent, led to 36% CR in patients with Ph+ ALL who had relapsed or were refractory to tyrosine kinase inhibitors (TKIs). 12 Information on the efficacy and safety of blinatumomab and TKI combination therapy remains very limited. Our patient had relapsed refractory Ph+ ALL that was complicated by invasive fungal infection during re-induction chemotherapy. Durable CR (7 months) was achieved with combination treatment of five cycles of blinatumomab and a third generation BCR-ABL TKI, which was well-tolerated. This case confirms the findings from a recent conference abstract reporting that six relapsed Ph+ ALL patients were treated with maximal of four cycles of blinatumomab in combination of TKIs (Andrey N Sokolov, ASH 2016 poster #4024). Furthermore, our case also signifies the non-myelosuppressive feature of blinatumomab (Figure 1) , which allowed successful anti-fungal treatment for an otherwise fatal infection in an immunocompromised patient.
Blinatumomab treatment also allowed successful treatment of another patient (patient no. 4) with relapsed pre-B ALL and pulmonary fungal disease. This patient was diagnosed with pre-B ALL at 11 years of age, and underwent chemotherapy and prophylactic cranial irradiation. She developed a BM relapse 32 months after completing therapy and was re-induced. Postinduction marrow demonstrated 0.5% blasts. Evaluation for febrile neutropenia revealed lung nodules consistent with fungal disease, and therefore to avoid prolonged neutropenia with additional chemotherapy, blinatumomab was initiated while receiving voriconazole ( Figure 1 ). She developed no greater than grade II toxicities. She achieved MRD-negative CR after a cycle of blinatumomab, which remained negative following a total of 3.5 cycles. She then underwent matched sibling BMT and remains in remission 410 months post BMT with 100% donor chimerism.
Blinatumomab treatment has also shown benefits in patients no. 1 with relapsed refractory and no. 2 with primary refractory pre-B ALL. Molecular CR was achieved in both patients after two cycles of blinatumomab before proceeding to haploidentical bone marrow transplantation. Both patients remain in remission with 100% donor chimerism 19 months post BMT.
In summary, our experience with five pediatric patients with relapsed/refractory ALL strongly supports blinatumomab as an effective and well-tolerated bridge therapy to allogeneic HCT, resulting in 100% DFS at 9-19 months post transplant. Our case series, although limited, highlights the efficacy and safety of blinatumomab in treating a high-risk pediatric patient who failed CAR-T cell therapies, a patient with Ph+ ALL on concomitant TKI treatment and patients with life-threatening systemic fungal infections. Our data are in partial agreement with the results of TOWER study, in which blinatumomab was superior to chemotherapy for Ph−ALL but contrasts in that, in the adult patients, transplant did not seem have a great impact upon survival in either group. 
